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A B S T R A C T
KRIT1 (CCM1) is a disease gene responsible for Cerebral Cavernous Malformations (CCM), a major cere-
brovascular disease of proven genetic origin affecting 0.3–0.5% of the population.
Previously, we demonstrated that KRIT1 loss-of-function is associated with altered redox homeostasis and
abnormal activation of the redox-sensitive transcription factor c-Jun, which collectively result in pro-oxidative,
pro-inflammatory and pro-angiogenic effects, suggesting a novel pathogenic mechanism for CCM disease and
raising the possibility that KRIT1 loss-of-function exerts pleiotropic effects on multiple redox-sensitive me-
chanisms.
To address this possibility, we investigated major redox-sensitive pathways and enzymatic systems that play
critical roles in fundamental cytoprotective mechanisms of adaptive responses to oxidative stress, including the
master Nrf2 antioxidant defense pathway and its downstream target Glyoxalase 1 (Glo1), a pivotal stress-re-
sponsive defense enzyme involved in cellular protection against glycative and oxidative stress through the
metabolism of methylglyoxal (MG). This is a potent post-translational protein modifier that may either con-
tribute to increased oxidative molecular damage and cellular susceptibility to apoptosis, or enhance the activity
of major apoptosis-protective proteins, including heat shock proteins (Hsps), promoting cell survival.
Experimental outcomes showed that KRIT1 loss-of-function induces a redox-sensitive sustained upregulation
of Nrf2 and Glo1, and a drop in intracellular levels of MG-modified Hsp70 and Hsp27 proteins, leading to a
chronic adaptive redox homeostasis that counteracts intrinsic oxidative stress but increases susceptibility to
oxidative DNA damage and apoptosis, sensitizing cells to further oxidative challenges. While supporting and
extending the pleiotropic functions of KRIT1, these findings shed new light on the mechanistic relationship
between KRIT1 loss-of-function and enhanced cell predisposition to oxidative damage, thus providing valuable
new insights into CCM pathogenesis and novel options for the development of preventive and therapeutic
strategies.
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1. Introduction
Cerebral cavernous malformation (CCM), also known as cavernous
angioma or cavernoma, is a major vascular dysplasia occurring mainly
within the central nervous system (CNS) and consisting of closely
clustered, abnormally dilated and leaky capillaries [1,2]. CCM lesions
have a prevalence of 0.3–0.5% in the general population and can ap-
pear as single or multiple (up to hundreds) mulberry-like vascular si-
nusoids of varying size, lined by a thin endothelium devoid of normal
vessel structural components, such as pericytes and astrocyte end-feet.
They can remain asymptomatic throughout life or result in clinical
symptoms of various type and severity at any age, including recurrent
headaches, focal neurological deficits, seizures, stroke and intracerebral
hemorrhage (ICH) [1–3].
This cerebrovascular disease is of proven genetic origin, and may
arise sporadically or is inherited as autosomal dominant condition with
incomplete penetrance and highly variable expressivity, including wide
inter-individual differences in lesion number, size and susceptibility to
ICH even among family members of similar ages carrying the same
disease-associated genetic defect [4]. Genetic studies have identified
three disease genes, KRIT1 (also known as CCM1), CCM2 and PDCD10
(also known as CCM3) [5], whose functions need to be severely im-
paired for pathogenesis. Indeed, most of the more than one hundred
distinct causative mutations identified so far in these genes are loss-of-
function mutations. In particular, mutations of the KRIT1 gene account
for over 50% of familial cases (up to 70% in Hispanic Americans) [5].
This gene encodes for a 736 amino acid protein that has been im-
plicated in the maintenance of endothelial cell-cell junction stability
and blood-brain barrier (BBB) integrity through the regulation of major
cell structures and signaling mechanisms, including cadherin-mediated
cell-cell junctions [6], integrin-mediated cell-matrix adhesion [7,8],
Rho GTPase-mediated cytoskeleton dynamics [9,10], and TGFβ-driven
endothelial-to-mesenchymal transition (EndMT) [11]. In addition, in
recent years it has become clear that KRIT1 plays an important role in
controlling signaling pathways involved in cell responses to oxidative
stress and inflammatory events [12–21]. In particular, original findings
demonstrated that KRIT1 loss-of-function is associated with increased
intracellular levels of reactive oxygen species (ROS) and enhanced cell
susceptibility to oxidative stress-mediated molecular dysfunctions and
oxidative damage [15]. Moreover, subsequent findings showed that
KRIT1 may exert a protective role against oxidative stress by limiting c-
Jun-dependent redox pathways [16] and defective autophagy [18–20].
Accordingly, recent evidence in animal models has suggested that
oxidative stress is linked to the pathogenesis of CCM disease and may
play an even more critical role than previously described due to sys-
temic effects [14]. Furthermore, growing data in cellular and animal
models indicate that limiting ROS accumulation and oxidative stress via
distinct approaches may contribute significantly in preventing or re-
versing CCM disease phenotypes [14,16–18,20,22].
Despite the significant progress in understanding CCM pathogen-
esis, no direct therapeutic approaches for CCM disease exist so far other
than the surgical removal of accessible lesions in patients with re-
current hemorrhage or intractable seizures [3]. Moreover, specific
pharmacological strategies are also required for preventing the de novo
formation of CCM lesions and counteracting disease progression and
severity in susceptible individuals, including CCM gene mutation car-
riers. Indeed, while the great advances in knowledge of physiopatho-
logical functions of CCM proteins have led to an explosion of disease-
relevant molecular information, they have also clearly indicated that
loss-of-function of these proteins has potentially pleiotropic effects on
several biological pathways, thus bringing new research challenges for
a more comprehensive understanding [20,21]. In particular, further
investigation into the emerging role of KRIT1 in redox-sensitive path-
ways and mechanisms is required to gain a better understanding of the
likely complex signaling networks underlying the physiopathological
functions of this important protein, thus facilitating the development of
novel strategies for CCM disease prevention and treatment.
A fundamental mechanism that governs cellular adaptive defense
against endogenous and exogenous oxidative stress is the activation of
the redox-sensitive transcription factor Nrf2 (nuclear factor erythroid 2-
related factor 2), which controls constitutive and inducible expression
of a plethora of antioxidant responsive element (ARE)-driven genes
involved in detoxification of reactive oxidants and maintenance of
cellular homeostasis [23–25]. Nrf2 is in fact the master regulator of
cytoprotective responses to counteract oxidative and electrophilic stress
through the coordinated induction of major antioxidant and phase II
detoxification enzymes. These cytoprotective pathways may in turn
prevent apoptosis and enhance cell survival by attenuating oxidative
damage, mitochondrial dysfunction, and inflammation, and increasing
cellular defense and repair mechanisms, thus playing a critical role in
protection against various diseases, including vascular diseases [25,26].
In particular, activation of the essential Nrf2/ARE antioxidant defense
pathway and its key downstream target heme oxygenase-1 (HO-1)
within the neurovascular unit (NVU) has been shown to protect the
cerebral vasculature against oxidative stress-mediated BBB breakdown
and inflammation in stroke [27,28].
Besides HO-1, Glyoxalase 1 (Glo1) is emerging among the major
downstream targets of Nrf2 transcriptional activity as a crucial stress-
responsive defense protein for cellular protection against both di-
carbonyl glycation and oxidative stress [29]. Glo1 is an ubiquitous
glutathione-dependent enzyme that plays a critical cytoprotective role
in limiting intracellular accumulation and toxicity of methylglyoxal
(MG), a highly reactive dicarbonyl compound that is inevitably formed
as a by-product of metabolic pathways, such as glycolysis [30]. MG
readily reacts with lipids, nucleic acids and proteins (particularly with
nucleophilic groups on side chains of Arg, Lys and Cys residues) to form
the heterogeneous family of advanced glycation end-products (AGEs)
[31,32]. MG-derived dicarbonyl adducts exert complex pleiotropic ef-
fects on normal and pathologic processes in cells, including modulation
of protein biological activity [33] and stability [34], and generation of
ROS and oxidative stress [35,36], which may culminate in distinct
biological outcomes [36–41]. In particular, supra-physiological accu-
mulation of argpyrimidine (AP), a major AGE formed by spontaneous
reaction between MG and protein arginine residues [40], has been
shown to induce oxidative DNA damage and apoptosis [39–42]. How-
ever, post-translational modifications (PTM) by MG-derived AP can also
enhance the functionality of fundamental stress-inducible proteins im-
plicated in cellular recovery after exposure to damaging stimuli and
protection against apoptosis, including heat shock protein 27 (Hsp27),
thus playing an important role in cell survival [43,44]. Furthermore,
there is also evidence that some MG-derived AGEs, including AP, are
endowed with antioxidant properties [45]. These apparently divergent
functions imply that MG, like other reactive species, may exert different
or even opposite biological effects, depending on its levels and the
cellular context. Interestingly, Glo1 and MG-derived AGEs have been
shown to play major and complex roles in vascular physiology and
pathophysiology, including the pathogenesis of brain microvascular
endothelial barrier dysfunctions [46–48].
The present study was designed to assess the putative involvement
of major regulators of cellular responses to oxidative stress, including
Nrf2 and Glo1, in the emerging relationship between KRIT1 loss-of-
function and enhanced cell sensitivity to oxidative challenges [21].
2. Materials and methods
2.1. Cell culture and treatment
KRIT1-/- and KRIT1+/+ mouse embryonic fibroblast (MEF) cell lines
were established from KRIT1-/- and KRIT1+/+ E8.5 mouse embryos,
respectively, whereas KRIT1 9/6 MEFs were obtained by infecting
KRIT1-/- cells with a lentiviral vector encoding KRIT1 [15]. Cells were
cultured at 37 °C and 5% CO2 in Dulbecco's modified Eagle's medium
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(DMEM) supplemented with 10% fetal calf serum (FCS), 2 mM gluta-
mine, and 100 U/ml penicillin/streptomycin.
The human brain microvascular endothelial cells (hBMEC) were
purchased from ScienCell Research Laboratory (Carlsbad, CA), and
cultured at 37 °C and 5% CO2 on cell culture dishes coated with rat tail
collagen type-I (BD Biosciences, San Jose, CA) and containing EGM-
2MV medium (Lonza, Basel, Switzerland), following manufacturer's
instructions.
Cells grown in complete culture medium were either mock-treated
or treated with specific compounds, including the mitochondria-
permeable superoxide dismutase (SOD) mimetic Tiron (4,5-dihydroxy-
1,3-benzenedisulfonic acid disodium salt monohydrate, Sigma-Aldrich,
Milan, Italy) (5 mM for 24 h), the JNK inhibitor SP600125
(Calbiochem-Merck, Darmstadt, Germany) (25 µM for 1 h) [16], and
the autophagy inducer Rapamycin (Calbiochem) (500 nM for 4 h) [18].
The given concentrations of these compounds were based on the out-
comes of previous works [16,18] and preliminary optimization ex-
periments, showing no significant toxicity to cells and optimal efficacy
in specific biochemical assays.
2.2. Cell transfection and siRNA-mediated gene silencing
For small interfering RNA (siRNA)-mediated KRIT1 knockdown,
hBMEC cells were subjected to a two-round transfection procedure with
a mix of four pre-designed iBONi siRNAs targeting KRIT1 (D-00101-
Plus, Ribbox GmbH, Germany) or an iBONi siRNA negative control (K-
00301-0005-N3, Ribbox GmbH), as previously described [18]. Briefly,
18–24 h before transfection, cells were plated at a density of 2 ×
105 cells/well in a 6-well plate with 2.5 ml complete EGM-2MV
medium per well, and reached 50–70% confluence at the time of
transfection. The transfection complex was prepared by mixing 25 nM
iBONi siRNAs and 1:166 HiPerFect reagent (Qiagen, Milan, Italy) in
serum-free growth medium and incubating at room temperature for
15 min, and added dropwise to the 6-well plates containing cells in
complete growth medium. Upon overnight incubation in the transfec-
tion mix, cells were washed and fed with complete EGM-2MV medium.
The siRNA transfection procedure was repeated after 48 h to obtain a
higher degree of knockdown; then cells were seeded into assay plates
and subjected to experimental conditions within 48–72 h. The KRIT1
knockdown efficiency was monitored by quantitative real-time poly-
merase chain reaction (qRT-PCR) and Western blotting (WB) analysis.
siRNA-mediated knockdown of Glo1 was performed as described in
[49].
2.3. RNA isolation, reverse transcription, and quantitative real time PCR
analysis (qRT-PCR)
Total cellular RNA was isolated using TRIzol Reagent (Invitrogen,
Milan, Italy). cDNA was then synthesized from 1 µg of RNA using the
RevertAid™ H Minus First Strand cDNA Synthesis Kit (Carlo Erba,
Milan, Italy). To quantify transcript expression levels, an optimal Sybr
Green or TaqMan real-time PCR assay was designed for Glo1 or the
appropriate housekeeping genes, using Beacon Designer 4 software
(Stratagene), starting from published sequence data supplied by the
NCBI database. Sybr Green or TaqMan gene expression was performed
in triplicate on a MX3000 P Real-Time PCR System (Agilent
Technology, Milan, Italy). The sequences of oligonucleotide primers
and TaqMan probes used were as follows: Mus musculus Glo1: 5′-ac-
gacagacaaagccacctgattg-3′ (sense, 400 nM), 5′-agcccaagtgtgagcaga-
gagc-3′ (antisense, 400 nM); Mus musculus KLF2: 5′-cgcctcgggttcatttc-
3′ (sense, 600 nM), 5′-agcctatcttgccgtccttt-3′ (antisense, 600 nM); Mus
musculus KLF4: 5′-gtgccccgactaaccgttg-3′ (sense, 600 nM), 5′-
gtcgttgaactcctcggtct-3′ (antisense, 600 nM); Mus musculus GAPDH: 5′-
ccaatgtgtccgtcgtggat-3′ (sense, 600 nM), 5′-tgcctgcttcaccaccttct-3′ (an-
tisense, 600 nM); human Glo1: 5′-ctctccagaaaagctacactttgag-3′ (sense,
400 nM), 5′-cgagggtctgaattgccattg-3′ (antisense, 400 nM), 5′-FAM-
tgggtcgcatcatcttcagtgccc-TAMRA-3′ (TaqMan Probe, 200 nM); human
β-actin: 5′-cactcttccagccttccttcc-3′ (sense, 600 nM), 5′-acag-
cactgtgttggcgtac-3′ (antisense, 600 nM), 50-TEXASRED-tgcggatgtc-
cacgtcacacttca-BHQ-3′ (TaqMan Probe, 200 nM). PCR reactions were
performed in a total volume of 25 μl, containing 250 ng of cDNA, 1X
Brilliant (or 1x Brilliant SYBR GREEN) QPCR master mix (Agilent
Technology), 0.5 μl of ROX Reference Dye (Agilent Technology) and a
concentration of specific primers and probes. The thermal cycling
conditions were as follows: 1 cycle at 95 °C for 10 min, followed by 45
cycles at 95 °C for 20 s and 55–60 °C for 1 min. Data for comparative
analysis of gene expression were obtained using the 2(-Delta
Delta C(T)) method [50].
2.4. Antibodies
Primary antibodies used in the present study included the following:
mouse anti-Methylglyoxal-AGE (Arg-Pyrimidine) mAb (clone 6B)
(BioLogo, Hamburg, Germany); rabbit anti-Nrf2 pAb (Bioss Antibodies,
Sial, Rome, Italy); rabbit anti-Nrf2 pAb (C-20) (Santa Cruz
Biotechnology); rabbit anti-Nrf2 pAb (ab31163, Abcam); rabbit anti-
Nrf2 mAb [EP1808Y] (AB62352, Abcam); rabbit anti-c-Jun pAb (H-79)
(Santa Cruz Biotechnology); mouse anti-phospho-c-Jun mAb (KM-1)
(Santa Cruz Biotechnology); mouse anti-Heme Oxygenase 1 mAb [HO-
1-1] (Abcam); rabbit anti-Bax pAb (N20) (Santa Cruz Biotechnology);
rat anti-Glyoxalase 1 mAb (6F10) (Santa Cruz Biotechnology); mouse
anti-p-JNK mAb (G-7) (Santa Cruz Biotechnology); rabbit anti Caspase-
3 pAb (9662, Cell Signaling Technology); rabbit anti phospho-Erk5
(Thr218/Tyr220) pAb (3371, Cell Signaling Technology); mouse anti-
Bcl-2 mAb (DAKO, Milan, Italy); mouse anti-Cytochrome c (Cyt c) mAb
(BD Pharmingen, Milan, Italy); mouse anti-Cyt c oxidase subunit IV
(Cox IV) mAb (Molecular Probes, Monza, Italy); goat anti-mouse KLF4
pAb (AF3158, R&D Systems); goat anti-human KLF4 pAb (AF3640, R&D
Systems); mouse anti-β-actin mAb (C4) (Santa Cruz Biotechnology);
rabbit anti-lamin β1 pAb (H-90) (Santa Cruz Biotechnology); mouse
anti-α-tubulin mAb (Sigma-Aldrich).
2.5. Protein extraction and western blotting
Extraction of total proteins was performed by lysing cells in pre-
cooled radioimmunoprecipitation assay (RIPA) lysis buffer. Lysates
enriched for mitochondria proteins were prepared by resuspending cells
in Mitobuffer and performing subcellular fractionation as described
previously [51]. For nuclear extracts, a FractionPREP Cell Fractionation
kit (Biovision, Vinci-Biochem, Florence, Italy) was used. Protein con-
centration in cell extracts was determined spectrophotometrically using
the BCA protein assay kit (Pierce, USA).
For WB, cell extract supernatants containing an equal amount of
proteins (20 µg) were treated with Laemmli buffer, boiled for 5 min,
resolved on either 10, 12 or 15% SDS-PAGE, and then blotted onto a
nitrocellulose membrane using iBlot Dry Blotting System (Invitrogen).
Unoccupied protein-binding sites were blocked by incubation with
Roti-Block for 1 h at room temperature, and membranes were then
incubated overnight at 4 °C with appropriate dilutions of specific pri-
mary antibodies. Subsequently, membranes were washed three times
with TBS/0.1% Tween-20 (TBST) for 10 min each, and incubated for
1 h at room temperature with the appropriate horseradish peroxidase
(HRP)-conjugated secondary antibody (Jackson ImmunoResearch) di-
luted 1:10000 in TBST. After three washes with TBST, antigen-antibody
complexes were then visualized by chemiluminescent detection of
peroxidase activity using the ECL system (Amersham Pharmacia, Milan,
Italy). As an internal control for protein loading, all membranes were
subsequently stripped in stripping buffer (100 mM 2-ME, 2% SDS, and
62.5 mM Tris-HCl, pH 6.8), and re-probed with antibodies for house-
keeping proteins, including α-tubulin, β-actin and lamin β1.
Protein bands from western blots were quantified by densitometry
using the ImageJ software, and their relative amounts were normalized
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to the levels of housekeeping proteins serving as internal loading con-
trols.
2.6. Immunohistochemical analysis
The study was performed according to the standards of the
Institutional Ethical Committee and the Helsinki Declaration, and was
approved by the ethic institutional review board for “Biobanking and
use of human tissue for experimental studies” of the Pathology Services
(“Azienda Ospedaliera Città della Salute e della Scienza” of Turin, and
Department of Medical Sciences of the University of Turin, Italy). All
patient records were anonymized and de-identified prior to analysis.
Histological samples of human CCM lesions were obtained from
archived, formalin-fixed, paraffin-embedded surgically resected CCM
specimens retrieved from the Department of Anatomy and Diagnostic
Histopathology at the University Hospital “Città della Salute e della
Scienza” of Turin, Italy. At the time of neurosurgery, an informed
consent was asked by neurosurgeons to patients (or legal re-
presentatives) for scientific use of residual materials, according to
Institutional Rules defined by the Ethical Committee of the University
Hospital “Città della Salute e della Scienza” of Turin. Only archived
specimens from KRIT1 loss-of-function mutation carriers with con-
firmed diagnosis of CCM by both neuroradiological and histopatholo-
gical analyses were included in the study. Most of the selected CCM
specimens were linked to patients carrying multiple CCM lesions.
Histological serial sections (2 µm thick) of selected paraffin-em-
bedded CCM specimens were prepared and routinely stained with he-
matoxylin and eosin (H&E). Two pathologists independently reviewed
the H&E-stained slides, whereas additional sections, collected on su-
perfrost plus slides, were used for immunohistochemical analysis.
Immunohistochemical (IHC) reactions were performed with a
Ventana Autostainer Benchmark Ultra (Ventana Medical Systems, Inc.)
as previously described [18]. Briefly, histological sections were depar-
affinized, rehydrated, and subjected to a 36-min cycle at boiling tem-
perature in citrate buffer (pH 6.0) for antigen retrieval. Endogenous
peroxidase activity was blocked by a 7-min incubation with H2O2 so-
lution RPE 6%. Thereafter, the sections were incubated for 32 min at
37 °C with an anti-Nrf2 primary antibody (diluted 1:100), followed by
incubation with Discovery Universal Secondary Antibody Ventana
(Roche). In particular, to confirm the specificity of IHC assays, we used
two distinct anti-Nrf2 antibodies validated for IHC in human tissues,
including the C-20 affinity purified rabbit polyclonal antibody (sc-722,
Santa Cruz Biotechnology), and the ab31163 rabbit polyclonal antibody
(lot. GR252439-11, Abcam). In addition, specific IHC analyses were
also performed to detect Glo1, phospho-JNK and KLF4 protein levels
(see Experimental Design, Materials and Methods in [49]). ICH labeling
was then developed by a 5- to 10-min incubation with 3,3′ diamino-
benzidine (DAB) + H2O2 substrate chromogen, which results in a
brown-colored precipitate at antigen site. The sections were subse-
quently counterstained with hematoxylin, and digitized at 40X mag-
nification using a Hamamatsu's High-Resolution Nanozoomer S210
whole slide scanner (Hamamatsu Photonics). Immunohistochemical
variables were scored by evaluating the percentage of stained nuclei at
a 40× magnification in endothelial lumens.
2.7. Affinity purification and identification of MG-derived argpyrimidine
protein adducts
Purification and identification of MG-derived AP protein adducts
was performed according to Sakamoto et al. [43].
2.8. Enzymatic activity assays
Cell extract preparation for enzymatic activity assays was performed
as previously described [42]. Briefly, cells were harvested and sus-
pended in 10 mM phosphate buffer pH 7.0, containing 1 mM
dithiothreitol (DTT) and 0.1 mM phenylmethanesulphonyl fluoride
(PMSF). Cell suspensions were then homogenized with a Potter-Hel-
vehjem homogenizer, centrifuged at 13,000×g for 30 min and the re-
sulting cell extracts used for enzymatic activities and protein content
measurements.
Glo1 activity was assayed according to Mannervik et al. [52]. The
assay solution contained 0.1 M sodium-phosphate buffer (PBS) pH 7.2,
2 mM MG, and 1 mM GSH. The reaction was monitored spectro-
photometrically by following the increase of absorbance at 240 nm and
25 °C, attributable to the formation of S-D-lactoylglutathione. One unit
activity is defined as 1 µmole of S-D-lactoylglutathione produced
min−1.
2.9. Assessment of cellular levels of reactive oxidative species
Assessment of cellular levels of reactive oxidative species, including
levels of general reactive oxygen species (ROS) and reactive nitrogen
species (RNS), was performed as a follow-up analysis of previously
published studies [15–18] using the membrane permeable 2′–7′-di-
chlorofluorescin-diacetate (H2DCF-DA) fluorogenic dye (Invitrogen).
Following cleavage of the acetate groups by intracellular esterases, the
resultant dichlorofluorescin (DCFH) is trapped intracellularly due to its
hydrophilicity, and oxidized by various ROS/RNS to form the highly
fluorescent 2′,7′-dichlorofluorescein (DCF), which can be detected by
fluorescence spectrophotometry or microscopy, thus serving as an ef-
fective indicator of generalized cellular oxidative stress. Briefly, MEF
and hBMEC cellular models described above were grown to confluence
in complete medium, washed twice with PBS, incubated with H2DCF-
DA at a final concentration of 5 µM in PBS at 37 °C for 30 min, and
analyzed by image-based cytometry with a Tali® Image-Based Cyt-
ometer (Invitrogen). Raw data were processed using the Flowing soft-
ware (v.2.5.0, by Perttu terho, University of Turku, Finland). Fluores-
cence readings were expressed as either relative fluorescence units
(RFU) or relative ROS/RNS level units. More specific measurements of
mitochondrial O2•− and H2O2 levels in the same cellular models were
performed previously using the superoxide indicator MitoSOX Red [15]
and the H2O2 sensor pHyPer-dMito (mt-HyPer probe) [18]. In addition,
further measurements of cellular H2O2 levels were performed with the
Amplex® Red Hydrogen Peroxide/Peroxidase Assay Kit (A22188, In-
vitrogen) (see Experimental Design, Materials and Methods, and Fig. 1
in [49]). However, as it is still not possible to exclude the involvement
of other oxidative species not yet analyzed in addition to O2•− and
H2O2, we resort to the use of the generic term ROS to refer to O2•− and
H2O2 as well as to secondary oxidative products that might be im-
plicated without certainty, according to the recommendations of
FRBM´s Editors [53].
2.10. DNA damage detection
DNA damage was detected by evaluating apurinic/apyrimidinic (AP
or abasic) sites by the DNA Damage - AP sites - Assay Kit (Colorimetric)
(ab65353, Abcam), according to the manufacturer's instructions.
Indeed, the AP site is one of the prevalent lesions of oxidative DNA
damage and its level is considered a good indicator of such damage. In
particular, Abcam's DNA Damage – AP Sites – Assay utilizes the ARP
(Aldehyde Reactive Probe) reagent that reacts specifically with an al-
dehyde group on the open ring form of AP sites. AP sites are then tagged
with biotin residues that can be quantified using a streptavidin-enzyme
(HRP) conjugate and an absorbance reader. Briefly, 500 ng of genomic
DNA were labeled with ARP containing a biotin moiety, immobilized in
microwells, and incubated with streptavidin-conjugated HRP. An HRP
substrate was then added, and the absorbance (650 nm) was measured
using a microplate absorbance reader. To translate the absorbance units
into the number of AP sites, a standard curve was obtained using
control DNA containing 40 AP sites per 105 bp, according to a pre-
viously published protocol [54].
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2.11. Apoptosis detection
Apoptosis was detected by evaluating DNA fragmentation by TdT-
mediated dUTP nick-end labeling (TUNEL) assay (ApoAlert® DNA
Fragmentation Assay, Clontech Laboratories, Inc., Mountain View, CA,
USA) [55].
2.12. Statistical analysis
Data were generated from three independent experiments and ex-
pressed as means± standard deviation (SD). One-way analysis of var-
iance with Dunnett's correction was used to assess differences among
groups. Statistical significance, determined by Student's t-test, was set
at p<0.05.
3. Results
3.1. KRIT1 modulates the expression of the anti-glycation enzyme
Glyoxalase 1 and the formation of MG-derived argpyrimidine protein
adducts
Previously, we showed that KRIT1 loss-of-function is associated
with increased intracellular ROS levels and enhanced cell susceptibility
to ROS-mediated molecular damage and cellular dysfunctions
[15,16,18].
To gain further insights into the role of KRIT1 in redox-sensitive
pathways and mechanisms underlying cell defense against oxidative
stress, we tested the effects of KRIT1 loss-of-function on the expression
levels of Glyoxalase 1 (Glo1), a major redox-dependent cytoprotective
enzyme involved in distinct cellular responses to oxidative stress, in-
cluding induction of epithelial-to-mesenchymal transition (EMT) and
apoptosis [37,38,42,55]. To this end, we took advantage of established
cellular models of CCM disease, including KRIT1-knockout MEF cells
and KRIT1-silenced human brain microvascular endothelial cells
Fig. 1. KRIT1 modulates the expression of the anti-glycation enzyme Glyoxalase 1 (Glo1) and the formation of MG-derived argpyrimidine protein adducts. Wild type (K+/+), KRIT1-/-
(K-/-), and KRIT1-/- re-expressing KRIT1 (K9/6) MEF cells grown to confluence under standard conditions were lysed and analyzed by Western blotting (a,d), qRT-PCR (b), and
spectrophotometric enzymatic assay (c) as described in Materials and Methods. a) Representative Western blot and quantitative histogram of the relative KRIT1 and Glo1 protein
expression levels. α-tubulin was used as internal loading control for WB normalization. The WB bands of Glo1 were quantified by densitometric analysis, and normalized optical density
values were expressed as relative protein level units referred to average value obtained for K9/6 samples. b) Glo1 mRNA expression levels were analyzed in triplicate by qRT-PCR and
normalized to the amount of an internal control transcript (GAPDH). Results are expressed as relative mRNA level units referred to the average value obtained for K9/6 cells, and
represent the mean (± SD) of n ≥ 3 independent qRT-PCR experiments. c) Glo1 enzyme activity was measured in cytosolic extracts according to a spectrophotometric method
monitoring the increase in absorbance at 240 nm due to the formation of S-D- lactoylglutathione. Glo1 activity is expressed in milliunits per mg of protein, where one milliunit is the
amount of enzyme that catalyzes the formation of 1 nmol of S-D-lactoylglutathione per min under assay conditions. Results represent the mean (± SD) of n≥ 3 independent experiments
performed in triplicate. d) Representative WB and quantitative histogram of argpyrimidine (AP) adducts as detected using a specific mAb. α-tubulin was used as internal loading control
for WB normalization. Western blots are representative of three separate experiments. **p≤ 0.01 versus K9/6 cells, ***p≤ 0.001 versus K9/6 cells. Notice that KRIT1 loss-of-function
leads to a significant increase in Glo1 expression and activity, and a decrease in the intracellular levels of major AP adducts of 70 and 27 kDa.
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(hBMEC), which previously allowed the identification of new molecules
and mechanisms involved in KRIT1 physiopathological functions,
opening novel therapeutic perspectives for CCM disease
[14–16,18,22,56,57].
Compared with wild-type (K+/+) and KRIT1-/- MEFs re-expressing
KRIT1 (K9/6) cells, KRIT1-/- (K-/-) cells displayed a significantly higher
expression of Glo1 both at protein (Fig. 1a) and mRNA levels (Fig. 1b),
suggesting that KRIT1 loss induces the upregulation of Glo1 expression.
To determine whether the observed increase in Glo1 transcript and
protein levels was paralleled by a similar trend at the functional level,
Glo1 specific enzymatic activity was examined by a spectrophotometric
method. The outcomes showed that Glo1 activity was significantly
higher in K-/- than K+/+ and K9/6 cells (Fig. 1c), suggesting that the
upregulation of Glo1 caused by KRIT1 loss is paralleled by increased
levels of Glo1 enzymatic activity.
Glo1 plays a key role in limiting intracellular accumulation of MG,
thereby modulating the formation and effects of MG-derived protein
glycation adducts [30]. Among these, argpyrimidine (AP) has been
shown to play a dual role in the regulation of important cellular pro-
cesses, including opposite effects on the apoptotic process, depending
on its concentration and the cell context. Specifically, high levels of AP
can promote cell death [39,40], whereas physiological levels are re-
quired to drive major cell survival mechanisms [43,44]. Thus, we ad-
dressed the possibility that the KRIT1 loss-dependent increase in Glo1
expression was accompanied by a decrease in the intracellular levels of
AP adducts. To this end, AP levels in protein extracts from K-/-, K+/+
and K9/6 cells were analyzed by WB with an antibody specifically di-
rected against AP adducts. As a result, we detected two major bands
with an approximate molecular weight of 70 and 27 kDa, whose in-
tensity was lower in K-/- compared to K+/+ and K9/6 cells (Fig. 1d),
indicating that the KRIT1 loss-dependent increase in Glo1 expression
and activity was indeed accompanied by a drop in the intracellular
levels of AP adducts.
3.2. The upregulation of Glyoxalase 1 and the downregulation of
intracellular levels of argpyrimidine adducts occur also in human brain
microvascular endothelial cells upon KRIT1 knockdown
To investigate whether the upregulation of Glo1 and the down-
regulation of AP adducts observed in K-/- MEF cells could be re-
capitulated in a different cellular model, more strictly connected to
CCM disease, we used hBMEC and performed KRIT1 knockdown ac-
cording to a previously optimized siRNA-based procedure [18]. No-
tably, this approach previously allowed us to demonstrate that KRIT1
knockdown in hBMEC leads to a significant increase in intracellular
ROS levels due to defective mitophagy [18]. In line with experimental
observations in K-/- MEF cells, we found that Glo1 was significantly
upregulated in KRIT1-silenced versus control hBMEC cells both at
protein (Fig. 2a), mRNA (Fig. 2b), and specific activity (Fig. 2c) levels.
Furthermore, these events were accompanied by an increase in in-
tracellular levels of oxidative species (Fig. 2d), and a reduced formation
of MG-derived AP adducts (Fig. 2e), demonstrating that the upregula-
tion of Glo1 and the downregulation of AP adducts induced by the loss-
of-function of KRIT1 can occur in different cellular models, including
brain microvascular endothelial cells.
3.3. The upregulation of Glo1 and the decrease of AP levels caused by
KRIT1 loss are redox-dependent
While it is well known that supra-physiological levels of MG cause
mitochondrial dysfunction, ROS formation, and oxidative stress-medi-
ated cellular injury [58,59], growing evidence indicates that Glo1 in-
duction plays an important role in molecular mechanisms underlying
cellular adaptive responses to oxidative stress [29,46]. Indeed, it has
been shown that the mammalian Glo1 gene contains a functional an-
tioxidant-response element (ARE), which serves to engage Glo1 in the
major cytoprotective antioxidant system controlled by Nrf2 [29], sug-
gesting that the stress-responsive transcriptional control of Glo1 pro-
vides a combined defense against both dicarbonyl glycation and oxi-
dative stress. Consistently, there is evidence that either MG- or H2O2-
induced oxidative stress leads to increased Glo1 mRNA, protein and
activity [29,30].
In this light, we tested whether the observed KRIT1 loss-mediated
upregulation of Glo1 and depletion of AP adducts were dependent on
the increase in intracellular ROS levels previously associated with
KRIT1 loss-of-function [15–18], including the increase in mitochondrial
superoxide anion (O2•−) and H2O2 levels detected by specific mi-
tochondrial probes [15,18]. To this end, we treated K-/-, K+/+ and K9/6
MEF cells with the SOD mimetic Tiron, a mitochondria-permeable su-
peroxide scavenger [60]. The outcomes of these experiments showed
that the reduction of cellular ROS/RNS levels occurring in K-/- cells
upon treatment with Tiron (Fig. 3a) was associated with a correspon-
dent significant reduction of Glo1 mRNA (Fig. 3b), protein (Fig. 3c) and
specific activity (Fig. 3d) levels, indicating that the upregulation of
Glo1 induced by KRIT1 loss is a redox-sensitive phenomenon. In addi-
tion, as assessed by WB analysis with a specific antibody, treatment of
K-/- cells with Tiron resulted also in an increase of AP adducts up to
levels found in untreated K+/+ cells (Fig. 3e,f), indicating that the
antioxidant Tiron could rescue both the increased expression of Glo1
and the decreased levels of AP adducts caused by KRIT1 loss-of-function
to near-physiological levels. These results were confirmed in KRIT1-
silenced hBMEC cells treated with Tiron (see Fig. 3a-c in [49]), de-
monstrating that KRIT1 downregulation causes a redox-sensitive up-
regulation of Glo1 and depletion of AP adducts in distinct cellular
models of CCM disease.
3.4. KRIT1 loss-dependent upregulation of Glo1 is part of a cell adaptive
response to oxidative stress involving the master redox-sensitive
transcriptional regulator Nrf2
To clarify the molecular mechanism underlying the KRIT1 loss-de-
pendent and redox-sensitive upregulation of Glo1, we investigated the
possible involvement of Nrf2, the master transcription factor that co-
ordinately regulates cellular defenses against oxidative stress through
the induction of genes coding for antioxidant and detoxification en-
zymes, including Glo1 [23,25,29,61,62]. To this end, nuclear and cy-
toplasmic extracts of K-/-, K+/+ and K9/6 cells were analyzed to ex-
amine the activation of Nrf2 by WB assessment of its nuclear
translocation. Indeed, an increased accumulation in the nucleus is a key
part of the Nrf2 activation mechanism, and the WB technique remains
the most widely used method to assess this change [23,61]. The out-
comes of these experiments demonstrated that the nuclear to cyto-
plasmic ratio of Nrf2 was significantly higher in K-/- than K+/+ and K9/
6 cells (Fig. 4a), suggesting that Nrf2 is activated in response to the loss-
of-function of KRIT1. Furthermore, consistent with the established
transcriptional control of Glo1 by Nrf2 [29], the increased nuclear
translocation of Nrf2 in K-/- versus K+/+ and K9/6 cells (Fig. 4a) re-
flected the upregulation of Glo1 mRNA and protein levels (Fig. 1a,b),
suggesting that KRIT1 loss-of-function leads to a sustained upregulation
of the Nrf2-Glo1 antioxidant pathway.
To test whether the observed activation of Nrf2 was a consequence
of the increase in intracellular ROS levels associated with KRIT1 loss-of-
function [15–18], we analyzed the effects of cell treatment with the
ROS scavenger Tiron, using nuclear c-Jun and phospho-c-Jun (P-c-Jun)
as controls. Indeed, we previously demonstrated that nuclear levels of
the phosphorylated active form of c-Jun, a critical component of the
redox-sensitive dimeric transcription factor complex AP-1 (activating
protein 1), are upregulated by KRIT1 loss-of-function in a redox-de-
pendent manner [16]. As shown in Fig. 4b, the antioxidant Tiron res-
cued both c-Jun and Nrf2 activation occurring in K-/- cells near to levels
of K+/+ and K9/6 cells, demonstrating that these activations were in-
deed redox-sensitive events linked to KRIT1 loss-of-function. Notably,
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the Tiron-mediated reduction of Nrf2 nuclear levels (Fig. 4b) reflected a
correspondent downregulation of Glo1 (Fig. 3b,c), which is consistent
with the reported redox-sensitive transcriptional regulation of Glo1
expression mediated by Nrf2 [29]. Furthermore, consistent with the
activation of Nrf2, we found that the increased nuclear translocation of
Nrf2 induced by KRIT1 loss-of-function (Fig. 4a,b) was associated with
the upregulation of heme oxygenase-1 (HO-1) (Fig. 4c), an established
Nrf2/ARE-regulated phase II antioxidant and detoxification enzyme
that is primarily involved in cytoprotection against oxidative stress-
induced cellular damage and apoptosis in various tissues, including the
vasculature [63–65]. Specifically, WB analysis showed a marked in-
crease in the expression levels of HO-1 in K-/- cells as compared with
K9/6 cells (Fig. 4c), which was significantly reduced upon cell treat-
ment with the antioxidant Tiron (Fig. 4c). All these results were re-
capitulated in KRIT1-silenced versus control hBMEC cells (see Fig. 4 in
[49]), further supporting the finding that KRIT1 loss-of-function leads
to the redox-sensitive activation of Nrf2 and consequent upregulation of
its downstream targets HO-1 and Glo1.
Remarkably, as hypothesized previously [21], we could also de-
monstrate that even other molecular signatures already associated with
KRIT1 loss-of-function, including the upregulation of ERK5 phosphor-
ylation and KLF2/4 expression [66], are redox-dependent and can be
rescued by the antioxidant Tiron both in KRIT1-knockout MEF and in
KRIT1-silenced hBMEC cells (see Fig. 6 in [49]), suggesting that they
could be part of the abnormal adaptive response to altered redox
homeostasis and signaling identified herein.
3.5. Defective autophagy and JNK activation contribute to the sustained
upregulation of Nrf2 and Glo1
Previously, we found that the upregulation of c-Jun induced by
KRIT1 loss-of-function could be attributed at least in part to a redox-
Fig. 2. The upregulation of Glyoxalase 1 (Glo1) and the downregulation of argpyrimidine adducts occur also in human brain microvascular endothelial cells upon KRIT1 knockdown.
Human brain microvascular endothelial cells (hBMEC) grown under standard conditions were mock transfected (CTR) or transfected with either KRIT1-targeting siRNA (siKRIT1) or a
scrambled control (siCTR). Cells were then either lysed and analyzed by Western blotting (a,e), qRT-PCR (b), and spectrophotometric enzymatic assay (c), or treated with H2DCF-DA for
measurement of cellular levels of general reactive oxidative species by image-based cytometry (d), as described in Materials and Methods. a) Representative WB and quantitative
histogram of the relative KRIT1 and Glo1 protein expression levels in si-CTR and si-KRIT1 cells. β-actin was used as internal loading control for WB normalization. The WB bands of Glo1
were quantified by densitometric analysis, and normalized optical density values were expressed as relative protein level units referred to the average value obtained for si-CTR samples.
b) Glo1 mRNA expression levels were analyzed in triplicate by qRT-PCR and normalized to the amount of an internal control transcript (human β-actin). Results are expressed as relative
mRNA level units referred to the average value obtained for control cells (CTR), and represent the mean (± SD) of n≥ 3 independent qRT-PCR experiments. c) Glo1 enzyme activity was
measured in cytosolic extracts of si-CTR and si-KRIT1 cells according to a spectrophotometric method monitoring the increase in absorbance at 240 nm due to the formation of S-D-
lactoylglutathione. Glo1 activity is expressed in milliunits per mg of protein, where one milliunit is the amount of enzyme that catalyzes the formation of 1 nmol of S-D-lactoylglutathione
per min under assay conditions. Results represent the mean (± SD) of n ≥ 3 independent experiments performed in triplicate. d) Measurement of cellular levels of general reactive
oxidative species. si-CTR and si-KRIT1 endothelial cells were left untreated or treated with H2DCF-DA, and DCF fluorescence intensity was analyzed by a Tali® Image-Based Cytometer.
The representative cytometer profile shows the increase in DCF fluorescence intensity in si-KRIT1 cells as compared to the control (si-CTR). e) Representative WB and quantitative
histogram of argpyrimidine (AP) adducts in si-CTR and si-KRIT1 endothelial cells as detected using a specific mAb. β-actin was used as internal loading control for WB normalization.
Western blots are representative of three separate experiments. **p ≤ 0.01 compared to control (CTR or si-CTR) cells. Notice that KRIT1 knockdown in human brain microvascular
endothelial cells leads to a significant increase in Glo1 expression and activity, and a decrease in the intracellular levels of major AP adducts of 70 and 27 kDa.
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Fig. 3. The upregulation of Glyoxalase 1 (Glo1)
and the decrease of argpyrimidine levels caused
by KRIT1 loss are redox-dependent. Wild type
(K+/+), KRIT1-/- (K-/-), and KRIT1-/- re-expres-
sing KRIT1 (K9/6) MEF cells grown to con-
fluence under standard conditions were either
mock-pretreated or pretreated with the ROS
scavenger Tiron (Tir). Cells were then either
treated with H2DCF-DA for measurement of
cellular levels of general reactive oxidative spe-
cies by image-based cytometry (a), or lysed and
analyzed by qRT-PCR (b), Western blotting
(c,e), and spectrophotometric enzymatic assay
(d) as described in Materials and Methods. a)
Measurement of cellular levels of general re-
active oxidative species. Cells mock-pretreated
or pretreated with Tiron (Tir) were left un-
treated or treated with H2DCF-DA, and DCF
fluorescence intensity was analyzed by a Tali®
Image-Based Cytometer. Fluorescence readings
were expressed as relative units of DCF fluores-
cence intensity referred to the average value
obtained for K9/6 cells. b-d) Glo1 mRNA, pro-
tein and specific activity levels in cells mock-
pretreated (-) or pretreated (+) with Tiron (Tir)
were analyzed and expressed as described in
Fig. 1a-c. e-f) Representative WB (e) and quan-
titative histogram (f) of intracellular levels of
argpyrimidine (AP) adducts in cells mock-pre-
treated (-) or pretreated (+) with Tiron (Tir).
WB analysis and densitometric quantification of
WB bands were performed as described in
Fig. 1d. Results are representative of n ≥ 3 in-
dependent experiments, and histograms re-
present quantifications expressed as means±
SD. **p≤ 0.01 versus K9/6 cells; ***p≤ 0.001
versus K9/6 cells. Notice that the normalization
of intracellular ROS levels induced by cell pre-
treatment with the antioxidant Tiron was ac-
companied by the rescue of Glo1 upregulation to
near-physiological levels, as well as by increased
levels of AP adducts.
Fig. 4. KRIT1 loss-dependent upregulation of Glo1 is part of a cell adaptive response to oxidative stress involving the master redox-sensitive transcriptional regulator Nrf2. Wild type (K+/
+), KRIT1-/- (K-/-), and KRIT1-/- re-expressing KRIT1 (K9/6) MEF cells grown to confluence under standard conditions were left untreated (a) or either mock-pretreated (-) or pretreated
(+) with the ROS scavenger Tiron (b,c). Nuclear and cytoplasmic fractions (a,b) or total cell extracts (c) were then obtained and analyzed by Western blotting for the indicated proteins
as described in Section 2. Nuclear levels of p-c-Jun were used as a control of redox-dependent effect of KRIT1 loss-of-function [16]. Lamin-β1 and α-tubulin were used as internal loading
controls for WB normalization of nuclear and total/cytoplasmic proteins, respectively. (a,b,c) The histograms below their respective Western blots represent the mean (± SD) of the
densitometric quantification of three independent experiments. *p< 0.05 versus K9/6 cells, **p≤ 0.01 versus K9/6 cells, ***p≤ 0.001 versus K9/6 cells. Notice that the upregulation of
c-Jun and p-c-Jun nuclear levels induced by KRIT1 loss-of-function is paralleled by a marked nuclear accumulation of Nrf2 (a,b) and the upregulation of its downstream effector HO-1 (c),
both of which are significantly reverted by cell treatment with the ROS scavenger Tiron (b,c).
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dependent activation of c-Jun NH2-terminal kinase (JNK), a major up-
stream regulator of c-Jun [16]. Given that JNK has been reported to
modulate also the activation of Nrf2 [61], we addressed the possibility
that the redox-sensitive phosphorylation/activation of JNK associated
with KRIT1 loss-of-function [16] could reside upstream of the upregu-
lation of Nrf2 and its targets HO-1 and Glo1. Consistently, treatment of
K-/- cells with the SP600125 JNK inhibitor under the same conditions
previously shown to normalize phospho-c-Jun levels [16] resulted in a
significant inhibition of the increased nuclear localization of Nrf2
(Fig. 5a), and accompanying upregulation of HO-1 (Fig. 5b) and Glo1
(Fig. 5c,d) observed in untreated K-/- cells, indicating that these effects
are indeed influenced by the redox-sensitive activation of JNK.
In addition, given our previous findings demonstrating that KRIT1
loss-of-function causes defective autophagy [18], we tested whether the
sustained activation of Nrf2 observed in KRIT1-null cells could be re-
versed by autophagy inducers, such as rapamycin. Indeed, whereas
autophagy can be included in the cellular antioxidant systems as it
contributes to clearing cells of damaged ROS-generating organelles and
harmful oxidized biomolecules [67,68], there is clear evidence that
defective autophagy results in prolonged Nrf2 activation due to accu-
mulation of p62, a selective autophagy substrate that can bind and
sequester Keap1, the negative regulator of Nrf2 [69,70]. Using the same
experimental conditions previously shown to rescue molecular pheno-
types associated with defective autophagy, including ROS and p62 ac-
cumulation [18], we found that treatment of K-/- cells with rapamycin
reduced both the increased nuclear localization of phospho-c-Jun and
Nrf2 (Fig. 5e), and the upregulation of HO-1 and Glo1 (Fig. 5f-h),
showing that defective autophagy underlies these KRIT1 loss-dependent
effects.
Taken together, these results suggest that defective autophagy and
redox-dependent activation of JNK induced by KRIT1 loss-of-function
contribute to the redox-sensitive activation of Nrf2 and consequent
upregulation of its downstream effectors HO-1 and Glo1. In turn, the
activation of these Nrf2-mediated stress response pathways could re-
present an adaptive mechanism by which cells sense and respond to the
increased intracellular levels of oxidative species and consequent redox
changes caused by KRIT1 loss-of-function.
3.6. Enhanced nuclear accumulation of Nrf2 occurs in endothelial cells
lining human CCM lesions
Previously, we demonstrated that markers of either oxidative/
Fig. 5. Defective autophagy and JNK activation associated with KRIT1 loss-of-function contribute to the sustained upregulation of Nrf2 and its downstream effectors HO-1 and Glo1. Wild
type (K+/+), KRIT1-/- (K-/-), and KRIT1-/- re-expressing KRIT1 (K9/6) MEF cells grown to confluence under standard conditions were either mock-pretreated (-) or pretreated (+) with the
JNK inhibitor SP600125 (a-d), or the autophagy inducer Rapamycin (e-h). Nuclear and cytoplasmic fractions or total cell extracts were then obtained and analyzed by Western blotting
(a-c, e-g) and spectrophotometric enzymatic assay (d,h) for the indicated proteins, as described in Materials and Methods and Fig. 1a-c. Nuclear levels of p-c-Jun were used as a control of
redox-dependent effect of KRIT1 loss-of-function. Lamin-β1 and α-tubulin were used as internal loading controls for WB normalization of nuclear and total/cytoplasmic proteins,
respectively. Histograms represent the mean (± SD) of n≥ 3 independent experiments performed in triplicate. **p≤ 0.01 and ***p≤ 0.001 versus K9/6 cells; °p≤ 0.05 and °°p≤ 0.01
versus mock-pretreated (-) cells. Notice that the redox-sensitive nuclear accumulation of Nrf2 and upregulation of its downstream effectors HO-1 and Glo1 induced by KRIT1 loss-of-
function were significantly reverted by cell treatment with either the JNK inhibitor SP600125 (a-d) or the autophagy inducer Rapamycin (e-h).
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inflammatory pathways, including P-c-Jun and COX-2, or defective
autophagy, including p62, are upregulated in the endothelium of
human CCM vessels [16,18]. Thereby, to examine the clinical relevance
of our novel findings demonstrating the upregulation of Nrf2 in cellular
models of CCM disease, we analyzed Nrf2 expression in human CCM
lesions. Indeed, whereas prolonged Nrf2 activation can result from ei-
ther pro-oxidant conditions [61] or defective autophagy [70], it has
been reported that nuclear accumulation of Nrf2 occurs in endothelial
cells of NVUs as an adaptive defense against blood-brain barrier
breakdown and cerebrovascular inflammation induced by oxidative
stress conditions [28,71]. Histological samples of human CCM lesions
were obtained from archived paraffin-embedded surgically resected
CCM specimens [18], and Nrf2 expression levels were evaluated by
immunohistochemical studies using two distinct anti-Nrf2 antibodies
validated for IHC in human tissues (see Materials and Methods). The
IHC analysis of three distinct CCM specimens from KRIT1 loss-of-
function mutation carriers with confirmed diagnosis of CCM by both
neuroradiological and histopathological analyses revealed a sig-
nificantly increased nuclear accumulation of Nrf2 in several endothelial
cells lining the lumen of abnormally dilated CCM vessels as compared
with perilesional normal vessels (Fig. 6), demonstrating that the nuclear
accumulation of Nrf2 caused by KRIT1 loss-of-function occurs also in
vivo and suggesting a potential relationship with CCM disease. Fur-
thermore, additional IHC analyses showed that, besides enhanced nu-
clear localization of Nrf2, endothelial cells lining human CCM lesions
express also increased levels of Glo1 and active, phosphorylated JNK
(phospho-JNK) as compared with perilesional normal vessels (see Fig. 2
in [49]), thus confirming and extending the results obtained in MEF and
hBMEC cellular models. Notably, the observation that activation of the
JNK pathway may also occur in endothelial cells lining human CCM
lesions is consistent with our previous study showing an enhanced
nuclear accumulation of phospho-c-Jun in these cells [16].
Taken together, the outcomes of our IHC analyses demonstrated
that only endothelial cells lining human CCM lesions, but not those of
perilesional normal brain vessels, showed a significant positive staining
for the target antigens assayed, including Glo1, phospho-JNK, and nu-
clear Nrf2, suggesting that the upregulation of these antigens in brain
endothelial cells is likely influenced by a combination of genetic and
environmental factors.
3.7. The redox-sensitive upregulation of Glo1 induced by KRIT1 loss-of-
function is associated with the downregulation of AP-modified heat shock
proteins Hsp70 and Hsp27
To understand the biological significance of the observed redox-
sensitive upregulation of Glo1 and consequent downregulation of in-
tracellular levels of AP adducts induced by KRIT1 loss-of-function, we
attempted to identify the 70 kDa and 27 kDa AP-modified proteins that
resulted differentially expressed in K-/- versus K+/+ and K9/6 MEF cells
(Fig. 1d). To this end, AP-modified proteins were purified from the
lysate of K9/6 MEF cells by immunoaffinity chromatography with the
anti-AP mAb. Column chromatography fractions containing the eluted
70 kDa and 27 kDa AP-modified proteins were identified by SDS-PAGE
and staining with Coomassie Blue (Fig. 7a). To determine their identity,
the isolated 70 kDa and 27 kDa AP-modified proteins were then di-
gested and resolved as individual peptides by HPLC. As a result, the
respective internal peptides were identified as mouse heat-shock pro-
tein 70 (Hsp70) and 27 (Hsp27) upon comparison with standard se-
quencing databases in the public domain (BLAST) (Fig. 7a), suggesting
that KRIT1 loss-of-function leads to the downregulation of AP-modified
Hsp70 and Hsp27 proteins.
3.8. The redox-sensitive decrease of AP-modified Hsp70 and Hsp27 levels
induced by KRIT1 loss-of-function is associated with an increased cell
susceptibility to oxidative DNA damage and apoptosis
Hsp70 and Hsp27 have been described as potent anti-apoptotic
proteins, being implicated in protection against apoptosis induced by a
variety of physical and chemical stresses, including heat shock and
oxidative stress [72–74]. Indeed, in addition to their generally accepted
role in removing or repairing denatured proteins and preventing pro-
tein aggregation, Hsp27 and Hsp70 have also been shown to interact
with DNA repair enzymes and related proteins involved in cell re-
sponses to oxidative stress, thus concurring in protecting cells from
Fig. 6. Nuclear accumulation of Nrf2 in endothelial
cells lining human CCM lesions. Nrf2 im-
munohistochemical (IHC) staining in histological
sections of human CCM surgical specimens deriving
from a KRIT1 loss-of-function mutation carrier. a,b)
Hematoxylin/eosin (H&E) (a) and Nrf2 IHC (b)
staining of a representative CCM surgical sample
containing normal vessels in a perilesional area (left
side, box c), which served as an internal negative
control, and a large CCM lesion lined by a thin en-
dothelium (right side and box d). c,d) Magnifications
of the two representative areas indicated in panel
(b). Notice that endothelial cells lining the lumen of
normal vessels are negative for Nrf2 nuclear staining
(panel c and magnified inset), while a significant
positive Nrf2 nuclear staining is evident in en-
dothelial cells lining the lumen of CCM lesions (black
arrows, panel d and magnified inset). Scale bars: a,b
200 µm; c,d 50 µm, insets 30 µm.
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oxidative DNA damage [75–77]. In particular, emerging evidence de-
monstrates that AP modification of Hsp27 is necessary for its cytopro-
tective effects against oxidative damage and apoptosis [43,78,79]. In
this light, our finding that KRIT1 loss-of-function is associated with a
decrease in the AP-modified Hsp70 and Hsp27 levels prompted us to
test whether this reduction could correlate with an enhanced cell sus-
ceptibility to oxidative DNA damage and apoptosis. Consistently, when
we evaluated oxidative DNA damage and apoptotic cell death by ELISA-
based quantification of abasic sites in DNA and TUNEL assay respec-
tively, we found a significant increase in the background levels of
abasic sites and apoptotic cells in K-/- versus K+/+ and K9/6 MEF cells
(Fig. 7b,c). Notably, cell pre-treatment with Tiron leading to the nor-
malization of AP levels in K-/- cells (Fig. 3e,f) also resulted in the rescue
of enhanced background levels of DNA abasic sites and apoptosis near
the levels observed in K+/+ cells (Fig. 7b,c), suggesting that the redox-
sensitive decrease of AP-modified Hsp70 and Hsp27 levels induced by
KRIT1 loss-of-function is positively correlated with and may contribute
to increased cell susceptibility to oxidative DNA damage and apoptosis.
In addition, to address the possibility that downregulation of AP-
modified Hsps and increased apoptosis susceptibility caused by KRIT1
loss-of-function were consequent to the corresponding upregulation of
Glo1, we took advantage of a previously optimized siRNA-based pro-
cedure to perform Glo1 silencing and look at AP-modified Hsps and
apoptosis susceptibility [55,80]. Specifically, K-/- and K9/6 MEF cells
were transiently transfected with either a pool of four siRNAs targeting
Glo1 (siGlo1) or non-targeting siRNAs used as negative control (siCtr),
and AP-modified Hsp70 and Hsp27 levels and apoptosis were assayed
as described in Materials and Methods. The outcomes of these experi-
ments demonstrated that Glo1 silencing induced a significant rescue of
both the downregulation of AP-modified Hsps and the increased
apoptosis susceptibility associated with KRIT1 loss-of-function, sug-
gesting a functional relationship (see Fig. 5 in [49]).
3.9. Increased susceptibility to apoptotic cell death induced by KRIT1 loss-
of-function occurs through the intrinsic, mitochondria-mediated pathway
To clarify the mechanism underlying increased susceptibility to
apoptotic cell death induced by KRIT1 loss-of-function and associated
with a decrease in AP-modified Hsp70 and Hsp27 protein levels, we
investigated the involvement of the apoptotic mitochondrial pathway
by assessing the levels of key regulators, including the anti-apoptotic
Bcl-2 and pro-apoptotic Bax proteins. Indeed, whereas it is well-estab-
lished that the intrinsic, mitochondria-mediated pathway of cell death
is especially susceptible to ROS [81], there is also clear evidence that
the key regulators of this pathway are modulated by Hsps [72]. As
compared with K+/+ and K9/6 MEF cells, we found that K-/- cells,
which are characterized by a higher apoptotic rate (Fig. 7c), presented
significantly decreased levels of the anti-apoptotic Bcl-2 protein paral-
leled by markedly increased levels of the pro-apoptotic Bax protein
(Fig. 8a). In addition, we analyzed cytochrome c (Cyt c) release into the
cytosol and the activation of Caspase-3 (Casp-3), the final executioner
of the apoptotic pathway [73,82]. As compared with K+/+ and K9/6
MEF cells, a significant increase in Cyt c release into the cytosol and
activation of Casp-3 was demonstrated in K-/- cells by WB analysis
Fig. 7. KRIT1 loss-of-function is associated with a redox-sensitive downregulation of AP-modified heat shock proteins Hsp27 and Hsp70, and a redox-sensitive increase in cell sus-
ceptibility to oxidative DNA damage and apoptosis. a) Identification of the 70 kDa and 27 kDa AP-modified and redox-sensitive proteins downregulated in K-/- versus K+/+ and K9/6 MEF
cells (Figs. 1d and 3e). AP-modified proteins were purified from the lysate of K9/6 cells by immunoaffinity chromatography with an anti-AP mAb. Chromatography fractions containing
the eluted 70 kDa and 27 kDa AP-modified proteins were identified by SDS-PAGE and staining with Coomassie Blue. The isolated 70 kDa and 27 kDa AP-modified proteins were then
digested and resolved as individual peptides by HPLC. The respective internal peptides were identified as mouse heat-shock protein 70 (Hsp70) and 27 (Hsp27) upon comparison with
standard sequencing databases in the public domain (BLAST). b,c) Wild type (K+/+), KRIT1-/- (K-/-), and KRIT1-/- re-expressing KRIT1 (K9/6) MEF cells were either mock-treated or
treated with the ROS scavenger Tiron, and oxidative DNA damage (b) and apoptotic cell death (c) were evaluated by ELISA-based quantification of abasic sites in DNA and TUNEL assay,
respectively. Histograms represent the mean (± SD) of n≥ 3 independent experiments performed in triplicate. **p≤ 0.01 and ***p≤ 0.001 versus K9/6 cells; °p≤ 0.05 and °°p≤ 0.01
versus untreated cells. Notice that cell treatment with Tiron rescued the enhanced background levels of DNA abasic sites (b) and apoptosis (c) induced by KRIT1 loss-of-function (K-/-
cells) near to levels observed in K+/+ cells.
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(Fig. 8b), suggesting that the increased susceptibility to apoptotic cell
death induced by KRIT1 loss-of-function occurs through an enhanced
activation of the intrinsic, mitochondria-mediated apoptotic pathway.
4. Discussion
Loss-of-function mutations of the KRIT1 gene (CCM1) have been
clearly associated with the pathogenesis of Cerebral Cavernous
Malformations (CCM) [5]. However, accumulated evidence in en-
dothelial-specific conditional knockout mouse models demonstrates
that the development of CCM lesions occurs in stochastic, spatially and
temporally restricted patterns despite the pan-endothelial deletion of
CCM genes [83,84], indicating that homozygous loss of KRIT1 is not
fully sufficient for CCM disease pathogenesis, and suggesting a con-
tribution of additional factors other than disease-predisposing KRIT1
mutations [4,12].
Our previous findings demonstrated that KRIT1 is a new important
player in redox biology, showing that its loss-of-function causes the
upregulation of pro-oxidant and pro-inflammatory pathways, including
the redox-sensitive JNK/c-Jun/COX-2 signaling axis, and defective
autophagy, resulting in perturbation of redox homeostasis and
consequent molecular and cellular dysfunctions [15,16,18–20]. While
pointing to a novel mechanism for CCM disease pathogenesis whereby
the redox functions of KRIT1 may be relevant in preventing vascular
anomalies triggered by focal oxidative stress and inflammatory events
[21], these results raised new research challenges as to whether KRIT1
dysfunction exerts pleiotropic effects on multiple redox-sensitive sig-
naling pathways and mechanisms.
Here, we extend our previous findings showing that KRIT1 loss-of-
function leads to the persistent upregulation of critical cytoprotective
proteins that govern cell adaptive responses to oxidative stress, in-
cluding the master redox-sensitive transcription factor Nrf2 and the
anti-glycation enzyme Glo1, a transcriptional target of Nrf2 that plays a
critical role in the enzymatic defense against MG-mediated glycative
and oxidative stress [29,46]. Furthermore, we found that the KRIT1
loss-dependent induction of these two key elements in cell survival
responses to environmental stresses leads to distinct effects, including
the upregulation of phase II antioxidant enzyme heme oxygenase-1
(HO-1), and the downregulation of MG-derived protein glycation ad-
ducts, such as argpyrimidine (AP) adducts. More specifically, we de-
monstrated that KRIT1 loss-of-function causes a drop of intracellular
levels of cytoprotective AP-modified Hsp70 and Hsp27 heat shock
Fig. 8. The increased susceptibility to apoptotic cell death induced by KRIT1 loss-of-function occurs through the intrinsic, mitochondria-mediated pathway. Wild type (K+/+), KRIT1-/-
(K-/-), and KRIT1-/- re-expressing KRIT1 (K9/6) MEF cells were grown to confluence under standard conditions. Total cell extracts (a) or mitochondria and cytosolic fractions (b) were
then obtained, and proteins involved in the intrinsic, mitochondria-dependent apoptotic pathway, including the anti-apoptotic Bcl-2 and pro-apoptotic Bax proteins (a), and Cytochrome c
(Cyt c) and Caspase-3 (Casp-3) (b), were analyzed by Western blotting as described in Materials and Methods. Cox IV and α-tubulin were used as internal loading controls for WB
normalization of mitochondria and total/cytoplasmic proteins, respectively. Pro-Casp-3, intact protein; Casp-3, active fragment. A representative immunoblot is shown for each ex-
periment. Histograms alongside their respective Western blots represent the mean (± SD) of the densitometric quantification of three independent experiments. **p≤ 0.01 and ***p≤
0.001 versus K9/6 cells. Notice that the basal levels of Bcl-2 and Bax proteins in K-/- cells were significantly down-regulated and up-regulated, respectively, as compared with K+/+ and
K9/6 cells (a). In addition, a significant increase in Cyt c release into the cytosol and activation of Casp-3 was also evident in K-/- cells (b).
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proteins, leading to increased levels of oxidative DNA damage and
enhanced activation of the intrinsic, mitochondria-mediated apoptotic
pathway. Notably, all these effects were shown to be redox sensitive, as
they could be significantly reversed by cell treatment with the SOD
mimetic Tiron, a mitochondria-permeable antioxidant [60], suggesting
that they are part of a cell adaptive response to cope with increased
intracellular ROS levels and altered redox homeostasis caused by KRIT1
loss-of-function (Fig. 9a). Accordingly, it is well established that in-
creased ROS levels may induce oxidative damage but also activate
antioxidant response mechanisms that attenuate it [62]. However,
while acute, transient upregulation of the antioxidant response may
eliminate the stressor and restore cellular homeostasis, chronic anti-
oxidant responses require specific cellular adaptations and may occur at
the expense of normal intracellular redox signaling, thereby affecting
other redox-sensitive molecules and mechanisms, whose dysregulation
may ultimately result in enhanced cell susceptibility to exogenous
oxidative insults. Consistent with this paradoxical effect, there is
growing evidence that persistent hyperactivation of key transcription
factors involved in the maintenance of cellular redox homeostasis and
defense against oxidative stress, including Nrf2 and members of the
Krüppel-like factor (KLF) family, can result in an abnormal cellular
stress response that paradoxically reduces oxidative stress resistance
leading to disease [21,85,86]. Indeed, whereas it has been suggested
that enhanced nuclear localization and activation of Nrf2 may sensitize
endothelial cells to oxidative stress through a KLF2-mediated down-
regulation of SOD2 expression [87], the abnormally sustained activa-
tion of Nrf2 has been clearly associated with many pathogenic me-
chanisms of multiple human diseases, including vascular diseases
[62,88,89].
In this light, our novel findings that a significant nuclear accumu-
lation of Nrf2 occurs in both cellular models of CCM disease and en-
dothelial cells lining the lumen of human CCM vessels suggest that the
abnormally sustained activation of Nrf2 caused by KRIT1 loss-of-func-
tion may have a significant impact on CCM disease onset and pro-
gression, likely representing an either insufficient or aberrant cellular
adaptive response to cope with a focal increase in oxidative challenges
induced by local stressful events affecting the NVU. Further investiga-
tion in animal models of CCM disease should exploit this intriguing
novel perspective toward a more comprehensive understanding of CCM
disease pathogenesis and the identification of new disease biomarkers
and therapeutic strategies.
Consistent with our findings, there is evidence that ROS production
and stress sensitivity are significantly enhanced under conditions of
Nrf2 constitutive activation [90]. Furthermore, whereas it is well-
Fig. 9. Schematic models representing adaptive redox
responses and cellular states associated with KRIT1 loss-
of-function. a) Redox-sensitive pathways modulated by
KRIT1 functions. KRIT1 loss-of-function causes a persis-
tent activation of the major redox-sensitive transcription
factors c-Jun and Nrf2 and consequent upregulation of
downstream targets, including cycloxygenase-2 (COX-2),
heme oxygenase-1 (HO-1) and glyoxalase 1 (GLO1).
While the c-Jun/COX-2 axis promotes pro-oxidant and
pro-inflammatory effects, the Nrf2/HO-1 and Nrf2/GLO1
pathways mediate adaptive antioxidant responses that
counteract these effects by limiting ROS and MG in-
tracellular accumulation, thus contributing to reduce a
vicious cycle of oxidative stress and providing an adap-
tive defense for long-term cell survival. However, this
sustained adaptive redox homeostasis occurs at the ex-
pense of other cytoprotective mechanisms, including the
MG-dependent formation of cytoprotective AP-Hsp27
protein adducts, leading to enhanced cell susceptibility to
oxidative DNA damage and apoptosis, and sensitizing
cells to additional stressful insults. b) Spectrum of cel-
lular states associated with KRIT1 loss-of-function.
Cellular stress and defense responses associated with
KRIT1 dysfunctions can be viewed as distinct but over-
lapping components of a spectrum of cellular states that
ranges from basal homeostatic state, to adaptive stress
response, insufficient defense, and defense failure, each
of which can be defined in terms of the maintenance of
molecular and cellular functions within an acceptable
dynamic range. In turn, differences in expression and
functional levels of stress-responsive proteins and adap-
tive defense mechanisms acting within the range of each
cellular state may be influenced by genetic variation,
resulting in inter-individual differences in adaptive stress
responses and susceptibility to disease onset and pro-
gression. See text for details.
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established that Nrf2 activation exerts a major protective role against
oxidative and inflammatory stress in vascular cells [25,26,64], recent
emerging evidence has revealed the "dark" side of Nrf2, suggesting that
its activity does not always lead to a positive outcome and may accel-
erate the pathogenesis of some vascular diseases [91]. Accordingly,
many Nrf2 inducers exhibit hormetic properties with antioxidant ben-
eficial effects reported at nanomolar concentrations but pro-oxidant
toxic effects at higher concentrations [28,92], whereas constitutive
Nrf2 activation in mice can even lead to postnatal lethality [93].
Taken together, these considerations suggest that Nrf2 may serve as
a double-edged sword in cell responses to oxidative stress, with tran-
sient induction providing a feedback defense against excessive ROS
generation, and sustained activation promoting abnormal adaptive
modifications that affect ROS-based signal transduction, while limiting
ROS accumulation and meeting requirements for cell survival under
prolonged mild oxidative stress conditions [94].
With regard to potential regulatory mechanisms that could link
KRIT1 loss-of-function to the Nrf2 stress response system, we found that
the redox-sensitive activation of JNK may play a role, since inhibition of
JNK resulted in at least partial reversion of both Nrf2 activation and
accompanying upregulation of its downstream targets HO-1 and Glo1
associated with KRIT1 loss-of-function. Consistently, there is evidence
that the JNK signaling pathway plays an important role in Nrf2-de-
pendent regulation of ARE-mediated gene expression [61,95]. Fur-
thermore, we found that the sustained activation of Nrf2 and con-
comitant upregulation of downstream targets observed in KRIT1-null
cells can be reversed also by experimental conditions previously shown
to rescue defective autophagy and p62 accumulation caused by KRIT1
loss-of-function [18], suggesting that KRIT1 dysfunctions may play an
important role in the reported link between defective autophagy and
sustained activation of Nrf2. Indeed, overactivation of Nrf2 can occur
also as a consequence of defective autophagy through a noncanonical
mechanism involving direct interaction between p62, which accumu-
lates when the autophagic flux is impaired, and the Nrf2 negative
regulator Keap1 [67,69,70,85,96].
Interestingly, besides reducing Nrf2 activation, JNK inhibition and
autophagy induction reduced also c-Jun activation, suggesting that
defective autophagy and redox-sensitive JNK activation previously as-
sociated with KRIT1 loss-of-function [16,18] contribute to upregulation
of both c-Jun and Nrf2 redox-sensitive pathways (Fig. 9a).
Among the downstream targets of Nrf2, HO-1, also referred to as
Hsp32, has been clearly implicated in cellular defenses against oxida-
tive stress [25,97]. Indeed, the Nrf2-mediated upregulation of this an-
tioxidant enzyme is one of the earlier events in the adaptive response to
stress, and it has been proposed to play a key role in preserving vascular
homeostasis during stressful conditions, including protection of the
cerebral vasculature and BBB against oxidative stress-induced damage
[25,27,98]. Nonetheless, whereas there is evidence that HO-1 cyto-
protective activity may be impaired by inappropriate PTM occurring
during cellular adaptation to chronic stress conditions, it has also been
reported that the upregulation of HO-1 is not always beneficial for cells
[28,99,100]. Taken together, these considerations support the possibi-
lity that the redox-sensitive upregulation of HO-1 induced by KRIT1
loss-of-function contributes to Nrf2-mediated adaptive defense me-
chanisms that limit a vicious cycle of ROS production and oxidative
stress. However, the chronic activation of this adaptive stress response
mechanism could cause HO-1 activity to be ineffective or insufficient
for cytoprotective responses to additional stressful events occurring
over time, leading to homeostasis imbalance and cellular dysfunction
that may become irreversible (Fig. 9a,b).
Glo1, the ubiquitous key enzyme in the detoxification of α-ox-
oaldehydes, including MG, is emerging as another major downstream
target by which Nrf2 exerts its cytoprotective stress response functions
[29]. Indeed, transcriptional control of Glo1 by Nrf2 provides a stress-
responsive defense against MG-mediated glycative and oxidative stress,
which has been implicated in the pathophysiology of various cellular
dysfunctions and diseases, including brain microvascular endothelial
barrier dysfunction and vascular diseases [46–48]. Specifically, there is
clear evidence that MG accumulation at supra-physiological levels
causes chemical modifications of proteins, nucleic acids and lipids [31],
and intensifies the mitochondrial production of ROS [58,101], ulti-
mately exposing cells to glycative and oxidative stress and consequent
pleiotropic effects, including cellular dysfunctions, DNA damage and
apoptosis [42,58,59]. Nevertheless, there is also clear evidence that
physiological concentrations of MG play a role in cell signaling [102],
and are required to selectively modify and activate some apoptosis-
protective proteins, including formation of activating argpyrimidine
adducts with the anti-apoptotic heat shock protein Hsp27 [43,44],
thereby playing an important role in cell homeostasis and survival.
Thus, as many other molecules involved in redox signaling and cell
responses to oxidative stress, both Glo1 and MG can influence bio-
chemical pathways in both positive and negative ways, and it is known
that their dose-response curve, in terms of positive and negative effects,
is U-shaped. Specifically, too little Glo1 activity leads to excessive ac-
cumulation of MG and consequent enhanced glycative and oxidative
stress [31,103]. By contrast, too much Glo1 activity may reduce MG
levels below a physiological threshold required for PTM and activation
of important signaling and cytoprotective proteins, thus paradoxically
shifting the homeostatic balance toward enhanced sensitivity to en-
vironmental stresses [44,102].
In this light, our findings that KRIT1 loss-dependent upregulation of
Glo1 is accompanied by a drop of AP-modified Hsp70 and Hsp27 pro-
tein levels and an enhanced cell susceptibility to oxidative damage and
apoptosis, are consistent with both positive and negative effects of a
sustained activation of the Nrf2-Glo1 stress-responsive pathway, as a
critical adaptive mechanism to cope with persistent oxidative stress
conditions [29]. Indeed, while sustained activation of the Nrf2-Glo1
stress-responsive system can contribute to reduce a vicious cycle of
intracellular ROS production and oxidative stress induced by KRIT1
loss-of-function [16], providing an adaptive defense for long term cell
survival, this may occur at the expense of the emerging important role
of physiological levels of MG and MG-dependent protein adducts
[43,44,102]. In particular, whereas the putative enhanced anti-apop-
totic activity of AP-modified Hsp70 remains to be defined, there is clear
evidence that AP-modified Hsp27 is endowed with enhanced cytopro-
tective properties, including the capacity to increase cellular resistance
against a wide variety of physiological and environmental insults by
limiting oxidative damage and apoptosis and facilitating cellular re-
covery [43,44,78,79]. Thus, the excessive downregulation of AP-Hsp27
adducts in response to an abnormal upregulation of Glo1 could result in
enhanced cell susceptibility to stressful conditions. Consistently, there
is evidence that Glo1 overexpression and associated reduction of phy-
siological MG levels may increase the severity of certain brain diseases
in mice [104]. In addition, the finding that increased susceptibility to
apoptotic cell death induced by KRIT1 loss-of-function involves the
intrinsic, mitochondria-mediated pathway is consistent with our pre-
vious results showing enhanced mitochondrial dysfunctions in distinct
cellular models of CCM diseases [15,18], as well as with evidence that
the intrinsic apoptotic pathway is especially susceptible to ROS [81].
5. Conclusions
The novel findings reported herein add further complexity to the
already complex molecular puzzle involving KRIT1 and its pleiotropic
dysfunctional effects, demonstrating that KRIT1 loss-of-function leads
to an abnormal sustained activation of the Nrf2 stress defense system,
including a persistent upregulation of its downstream effectors HO-1
and Glo1. Consistently, there is evidence that Nrf2 activation may lead
to the simultaneous induction of HO-1 and Glo1 expression, providing a
coordinated adaptive endogenous defense against both oxidative and
glycative stress [105,106]. However, the sustained upregulation of
these pathways due to constitutive pro-oxidant and pro-inflammatory
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conditions, such as those caused by KRIT1 loss-of-function, may result
in a chronic adaptive redox homeostasis that sensitizes cells to addi-
tional stressful events (Fig. 9b). Specifically, because of the incapacity
of the stress-responsive defense systems to fully compensate for the
absence of KRIT1 and reconstitute the basal cellular homeostasis, KRIT1
loss-of-function leads to a persistent shift from a normal homeostatic
state to an adaptive stress response state, which results in cellular
adaptation to a chronic mild stress condition. In the absence of addi-
tional stressful events, cytoprotective molecular adaptations allow cells
to tolerate the low degree of deviation from the basal homeostatic state
and achieve biological stability within a new dynamic range, thus
leading to an adaptive homeostasis that preserves cell viability and
function [107,108]. However, adaptive homeostasis has some physio-
logical costs, including the cost of molecular changes required for cel-
lular adaptation, which make cells much more vulnerable to additional
internal perturbations and external insults. In fact, secondary stressful
events may exceed the insufficient capacity of a chronically activated
stress response system to defend the adaptive homeostatic state, leading
to progressive molecular and cellular dysfunctions and disease devel-
opment. Furthermore, differences in expression and functional levels of
stress-responsive proteins and adaptive defense mechanisms acting
within the range of either basal or adaptive homeostasis may be in-
fluenced by genetic variation, resulting in inter-individual differences
in adaptive stress responses and susceptibility to disease onset and
progression (Fig. 9b).
Overall, our findings extend the pleiotropic redox-sensitive func-
tions of KRIT1 and shed new light on molecular mechanisms underlying
the enhanced cell vulnerability to oxidative stress caused by KRIT1 loss-
of-function, thus providing novel insights into CCM pathogenesis and
treatment. Indeed, the development of pharmacological approaches
aimed at helping or supplementing the cellular stress-responsive de-
fense systems to better compensate for KRIT1 loss-of-function and re-
store cellular homeostasis back to the basal state, could evolve as a
novel promising preventive and therapeutic option for CCM disease.
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